Kornimate/medical-research-clean huggingface dataset:
participatory intervention among construction workers (irma11)

Conditions: Musculoskeletal Disorders

Summary: there is high prevalence of back pain and neck-shoulder pain among blue collar workers. physical excessive exposures such as heavy lifting or working with a bended or twisted back are independent risk factors for back pain among workers in the construction industry. participatory ergonomic initiatives increase the success of interventions aimed at reducing physical excessive exposures. the objectives are in two phases to; 1) determine which work-tasks in selected job-groups involve the highest load of the back and shoulders during a normal working day (using emg, actigraphs, video). 2) investigate whether a participatory intervention can reduce physical workloads, drawing on information from objective measurements from phase 1.


Eligibility criteria:
inclusion criteria: * full time construction workers who are member of a labor union and can read and understand danish. * the type of work must include manual work that involves lifting exclusion criteria: * life-threatening diseases * pregnancy * hypertension \>160/100 mmhg * unable to participate in the measurements
evaluation of microvolt t-wave alternans(mtwa) testing for the detection of active ischemia

Conditions: Coronary Artery Disease

Summary: mtwa-cad is a feasibility study designed to evaluate microvolt t-wave alternans (mtwa) testing for the purpose of detecting active ischemia in patients with known or suspected coronary artery disease (cad). mtwa is a subtle, alternating pattern in the t wave portion of the surface electrocardiogram (ecg) that is associated with increased risk of ventricular tachyarrhythmias and sudden cardiac arrest (sca).

ischemia, a common trigger for arrhythmias, is a well-documented cause of repolarization alternans. human studies have shown that active ischemia can be associated with visible as well as microvolt-level t-wave alternans. while mtwa testing is traditionally used to evaluate arrhythmic risk, this known association with ischemia may allow mtwa testing to be used as a diagnostic tool to detect underlying cad. the mtwa-cad study will assess the feasibility of this concept by measuring mtwa during routine nuclear stress testing or stress echocardiography with treadmill exercise. this is a feasibility study designed to verify preliminary observations under controlled environments and to generate hypotheses, endpoints, and sample sizes for future investigations.

Eligibility criteria:
inclusion criteria: * age 18 or above, or of legal age to give informed consent specific to state and national law * willing and capable of providing informed consent * willing and capable of undergoing a spect mpi exercise test (or stress echo) at an approved clinical investigational center * in normal sinus rhythm at the time of the exercise test * a life expectancy of more than 6 months exclusion criteria: * in atrial fibrillation at the time of the exercise test * left bundle branch block (precludes st segment measurement) * pacemaker-dependent * life expectancy of less than 6 months * pregnancy
obtaining and storing blood samples and debridement samples for wound related research

Conditions: Venous Insufficiency

Summary: the intent of this protocol is to obtain blood samples from subjects with or without a wound, so the blood can be used in wound-related scientific studies. it is also the intent of this protocol to salvage debrided wound material that is normally destined for destruction, so it can be used in wound-related scientific studies.

the samples will be studied in order to attempt to better understand wounds and their associated barriers to healing. analytical methods used to examine the blood or debridement can investigate morphological, molecular, immunological, cellular, viral, biochemical, chemical, genetic, and/or transcriptional components of the samples. it is the goal of this study to determine if these tests may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.

Eligibility criteria:
inclusion criteria: inclusion criteria for the collection of wound debridement 1. the subject must have a full thickness wound. 2. the subject must be a candidate for sharp debridement. 3. the subject must be 18 years of age or older. 4. the subject must be mentally competent as determined by the investigator inclusion criteria for the collection of blood wounded or otherwise not healthy subjects, subjects weighing less than 110 lbs., or subjects contributing 50ml of blood or less: 1. the subject must be 18 years of age or older. 2. the subject must be mentally competent as determined by the investigator. not wounded and healthy subjects weighing at least 110 lbs. who may contribute up to 500ml of blood: 1. the subject must be 18 years of age or older. 2. the subject must be mentally competent as determined by the investigator. 3. the subject must weigh at least 110 lbs. 4. the subject must have a hemoglobin level that is in or above the normal range within the last 8 (eight) weeks as determined by standard clinical laboratory testing, the copper sulfate test, or a point of care instrument. exclusion criteria: exclusion criteria for the collection of wound debridement and blood collection\* 1. the subject must not be currently incarcerated or pregnant. 2. the subject must not weigh less than 40 lbs. 3. if the subject will be contributing more that 50 ml of blood during an 8 (eight) week period, then the subject must not have donated red blood cells within the last 8 (eight) weeks.

Keywords: diabetic, venous insufficiency
topical liposomal amphotericin b gel treatment for cutaneous leishmaniasis

Conditions: Leishmaniasis

Summary: comparison between placebo gel treatment to topical liposomal amphotericin b gel treatment for cutaneous leishmaniasis of leishmania species major and tropica.

randomized, double blind, placebo controlled study. the study will include 108 patients with cutenous leishmaniasis of leishmania species major and tropica, confired by polymerase chain reaction of a sample from a lesion. cure rate will be compared between patients treated with amphotericin-b 0.4% liposomal gel and patients treated with placebo gel preparation.

Eligibility criteria:
inclusion criteria: * cutenous leishmaniasis confirmed by pcr (leishmania species major or tropica) * 1 to 5 lesions * signed informed consent exclusion criteria: * facial lesions * significant co-morbidity * pregnancy or breast-feeding at enrollment * previous treatment for leishmaniasis

Keywords: leishmania major leishmania tropica amphotericin b
relationship between smartphone addiction and temporomandibular joint disorders among adults in egypt.

Conditions: Temporomandibular Disorders; Smartphone Addiction

Summary: cross sectional study to investigate the relation between smartphone addiction and temporomandibular disorders among youth population in egypt. an online- based questionnaire study. a 296 participants who are egyptians with age between18 and 35 years old without prior neck and upper extremity related diseases, orofacial trauma or surgeries, history of rheumatoid arthritis or congenital musculoskeletal problems. an online- based questionnaire will be sent through different social media platforms, it will include three screens, the first includes the consent form, the second includes the demographic data (year of birth, current educational status, gender and geographic information ), and the third page includes questionnaires .


Eligibility criteria:
inclusion criteria: * both males and females adults * their ages between18 and 35 years old * ability to use smartphone exclusion criteria: * any neck and upper extremity related diseases * orofacial trauma or surgeries * history of rheumatoid arthritis * congenital musculoskeletal problems.

Keywords: tmj disorders
interrupting sedentary time to improve cardiometabolic health and toxicity in patients with lymphoma receiving chemotherapy: the istand trial

Conditions: Lymphoma; Lymphoma, Hodgkin; Lymphoma, Non-Hodgkin; Sedentary Behavior

Summary: this study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving r-chop or pola-r-chp chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.

the purpose of this study is to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving r-chop or pola-r-chp chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects. participants will be randomized into one of two groups: group a: interrupted sedentary time intervention vs. group b: usual care control group. randomized means a participant is placed into a study group by chance. the research study procedures include screening for eligibility, assessments of fitness and physical health, blood tests, and questionnaires. participation in this research study is expected to last about 3 months. it is expected that about 24 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * ability to understand and the willingness to sign informed consent prior to any study- related procedures. * patients diagnosed with lymphoma. * will receive first line r-chop or pola-r-chp chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis. * aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included. * engaging in ≤60-minutes of structured moderate or vigorous intensity exercise. * have physician clearance to participate in exercise. * speak english. * willing to travel to dana-farber cancer institute for necessary data collection and exercise sessions. * access to a phone that can receive text messages. exclusion criteria: * unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded. * participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention. * patients receiving treatment for other active malignancies (except basal cell carcinoma). this study is exclusively targeting lymphoma chemotherapy-related effects. * subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study. * unable to travel to dfci longwood campus for necessary data collection and chemotherapy infusions.

Keywords: lymphoma hodgkin lymphoma lymphoma, hodgkin lymphoma, non-hodgkin non-hodgkin lymphoma sedentary behavior
contegra versus pulmonary homograft for right ventricular outflow tract reconstruction in newborns

Conditions: Congenital Heart Defect; Right Ventricular Outflow Tract Reconstruction

Summary: pulmonary homografts are standard substitutes for right ventricular outflow tract reconstruction in congenital heart surgery. unfortunately shortage and conduit failure secondary to early calcifications and shrinking are observed particularly for small sized conduits in younger patients. in neonates, contegra® 12mm could be a valuable alternative, but conflicting evidence exists. this retrospective study compared the outcome of these two conduits in a newborn population.


Eligibility criteria:
inclusion criteria: neonatal patients who had a reconstruction of the right ventricular outflow tract with a pulmonary homograft or a contegra between january 1992 and december 2014 at huderf exclusion criteria: na
does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo?

Conditions: Ischemia Reperfusion Injury; Cardiovascular Disease

Summary: to study the impact of 3 day exposure to atorvastatin 80mg on annexin a5 targeting after ischemic exercise in the non-dominant forearm.

3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (also known as statins) have been found to reduce cardiovascular events. this protective effect has been traditionally explained by lowering plasma cholesterol and subsequent reduced progression of atherosclerosis. however in animal experiments statins have also shown the ability to induce pharmacologic preconditioning and thereby reduce infarct size. this effect contributes to the beneficial effect of statins on reducing of cardiovascular events. in order to differentiate between these two mechanisms of protection we will study the effect of atorvastatin on ischemia reperfusion damage after a short exposure to atorvastatin, before the lipid lowering effect of atorvastatin becomes apparent.

Eligibility criteria:
inclusion criteria: * male * age 18-50 years * informed consent * physical able to perform ischemic exercise exclusion criteria: * history of any cardiovascular disease * hypertension (in supine position: systole \> 140 mmhg, diastole \> 90 mmhg) * diabetes mellitus (fasting glucose \> 7.0 mmol/l or random glucose \> 11.0 mmol/l) * hyperlipidaemia (fasting total cholesterol \> 5.5 mmol/l) * alanine-amino-transferase (alat) \>90 u/l * creatinine kinase (ck) \>440 u/l * drug or alcohol abuse * concommitant chronic use of medication * administration of radioactivity in research setting during the last 5 years * participation to any drug-investigation during the previous 60 days as checked with vip check according to crcn standard procedures

Keywords: ischemia reperfusion injury atorvastatine preconditioning cardiovascular disease
evaluation of preoperative anxiety level based on the day of admission for cardiac surgery

Conditions: Cardiac Surgery

Summary: prospective, observational, non-randomized study that evaluates the impact of the admission day (j-1 vs j-0) on preoperative anxiety in cardiac surgery patients.

the goal of this study is to determine whether the admission day (j-1 or j-0) has a significant effect on preoperative anxiety using the apais (amsterdam preoperative anxiety and information) scale and to identify modifiable factors to improve patient care. this study includes 400 patients divided into two groups : 200 patients admitted the day before their surgery (j-1) and 200 patients admitted on the day of surgery (j-0). patients admitted for cardiac surgery at the university hospital of rennes will be invited to participate after verification of the inclusion criteria. a nurse or surgeon will explain the objectives and procedures of the study and provide the patient with an information and non-opposition letter. if the patient agrees, they will be included in the study, and the non-opposition form will be recorded in their medical file. patients will complete the questionnaire in two stages : upon admission and just before leaving for the operating room. the estimated time to complete the questionnaire is approximately 15 minutes, with 10 minutes for the first part and 5 minutes for the second part.

Eligibility criteria:
inclusion criteria: * aged over 18 years old * scheduled for cardiac surgery * have received written and oral information about the protocol * admitted to the cardiac and thoracic surgery units * not opposed to participating in the research. exclusion criteria: * patient undergoing emergency cardiac surgery with no time for reflection * legal adults under legal protection (guardianship, curators, or legal protection) * pregnant or breastfeeding women, minors, individuals unable to express consent * patient on long-term anxiolytic treatment * patient with psychiatric disorders, cognitive impairments, or central neurological disorders. * patient already participating in an ongoing study in the department of thoracic and cardiovascular surgery.

Keywords: preoperative anxiety cardiac surgery evaluation of anxiety admission day apais scale
risk profile for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the objective of this study is to assess the risk profile in patients with atrial fibrillation, which represents the degree of changes (remodeling) in the atrial tissue and which can help to predict in which patients rhythm control will be successful. this risk profile will consist of a combination of underlying (heart) disease and risk factors, as measured with use of parameters obtained with echocardiography, circulating biomarkers and other relevant clinical data. ultimately this risk profile can be used to guide type of (rhythm) control therapy in individual patients with atrial fibrillation.

atrial fibrillation is responsible for substantial morbidity and mortality.identification of patients with af that is difficult to treat may improve the outcome of rhythm control therapy. left atrial size or volume could be a useful tool to select patients that will benefit from rhythm control therapy.beside echocardiographic parameters,atrial fibrillation has been also associated with circulating biomarkers in blood like collagen metabolism, inflammatory mediators,neurohumoral factors and proteins/proteomic profiles. beside more accepted risk factors (myocardial ischemia, diabetes and pulmonary disease)other less well-known clinical factors (sleep apnea, alcohol or other intoxication abuse, excessive physical activity, esophageal problems and increased body mass index) may also predict the outcome of rhythm control.it seems also plausible that recurrent atrial fibrillation within one month after start of rhythm control is associated with a different risk profile than late atrial fibrillation recurrences.during this study we will try to identify patients with atrial fibrillation who are more or less likely to respond to rhythm control therapy.

Eligibility criteria:
inclusion criteria: * short-lasting symptomatic paroxysmal or persistent af; * rhythm control strategy is preferred; * no contra-indication for oral anticoagulation; * age \> 18 years; * written informed consent exclusion criteria: * total history of heart failure and/ or of severe valvular disease \> 3 years; * severe valvular disease; * acute coronary syndrome/ myocardial infarction/ percutaneous coronary intervention/ coronary artery bypass surgery within the past one month; * post-operative af.

Keywords: atrial fibrillation arrhythmia rhythm control
identification of prognostic gene mutations in biliary tract cancer using whole genome sequencing

Conditions: Biliary Tract Cancer

Summary: the purpose of this study is to investigate genetic mutations affecting prognosis using whole genome sequencing in patients with biliary tract cancer.

recently, as genome technology such as next-generation sequencing has progressed, precision medicine using genetic analysis in lung cancer, colorectal cancer, and melanoma has been actively studied. the need for such precision medicine is also increasing in biliary tract cancer patients. although whole genome sequencing is relatively costly, it is known to provide more accurate information than other methods such as exome analysis and rna sequencing in identifying promoter mutations, regulatory regions, and structural variants. pancreatic cancer and melanoma have been studied by whole genome sequencing, but there is no previous study using whole genome sequencing method in biliary tract cancer.

Eligibility criteria:
inclusion criteria: * patients diagnosed with biliary tract cancer via endoscopic retrograde cholangiopancreatogram exclusion criteria: * pregnancy * other active tumors within 5 years * coagulopathy * severe mental illness
metoclopramide vs placebo for prevention of pneumonia in acute stroke

Conditions: Acute Stroke; Aspiration Pneumonia

Summary: pneumonia is a major cause of mortality and morbidity in patients with acute stroke fed via nasogastric tubes and may be because of vomiting and gastro-esophageal regurgitation. the aim of the study was to assess whether regular treatment with metoclopramide, a d2-receptor antagonist with antiemetic and gastric prokinetic actions, could reduce the rate of pneumonia.

patients admitted with no signs of pneumonia within 7 days of stroke onset and 48 hours of insertion of a nasogastric tube will be recruited into a single-blind randomized placebo-controlled study who will admit in neurology department, pims. participants will receive metoclopramide 10 mg or placebo 3 times daily via the nasogastric tube for 4 days. clinical signs of pneumonia will be recorded on alternate days. pneumonia will be diagnosed if the patient has relevant clinical signs, high inflammatory markers, and new infiltrates on the chest radiograph. a sample size of 106 patients is calculated, 53 patients in each group. non-probability consecutive sampling will be used for recruitment of participants. study duration will be six months.

Eligibility criteria:
inclusion criteria: 1. patients of either gender. 2. patients within 7 days of acute ischemic or hemorrhagic stroke confirmed by computed tomographic scan of the brain who required nasogastric feeds for \>24 hours, and could be recruited within 48 hours of ngt insertion 3. age above 13 years. exclusion criteria: * patients with aspiration pneumonia at the time of presentation. * patients with a history of chronic neurodegenerative diseases that could affect swallowing (e.g. parkinson disease and motor neuron disease) * poor postural control (unable to sit up for swallowing assessment). * esophageal disorders, * contraindications to metoclopramide.
safety and efficacy of radiation plus tace and lenvatinib in advanced hcc with pvtt

Conditions: Advanced Hepatocellular Carcinoma

Summary: this is a multicentri prospective cohort study to investigate the safety and efficacy of external beam radiation (rt) combined with transarterial chemoembolization (tace) and lenvatinib vs tace and lenvatinib in the treatment of advanced hepatocellular carcinoma (hcc) with portal vein tumor thrombus (pvtt).


Eligibility criteria:
inclusion criteria: 1. age 18-75 years; 2. histologically or cytologically or clinically confirmed diagnosis of hcc; 3. presenting with pvtt and at least one measurable intrahepatic lesion on the basis of modified response evaluation criteria in solid tumors (mrecist); an intrahepatic lesion consisting of a single tumor (≤ 10.0 cm) or multiple tumors (≤ 3 foci) with the tumor burden \< 50%; 4. eastern cooperative oncology group (ecog) performance status score of 0 or 1; 5. child-pugh class a or b; 6. life expectancy of at least 3 months; 7. satisfactory blood, liver, and kidney function parameters. the acceptable blood, liver, and kidney parameters were (1) neutrophil count ≥ 1.5 × 109/l; (2) platelet count ≥ 60 × 109/l; (3) hemoglobin concentration ≥ 90 g/l; (4) serum albumin concentration ≥ 30 g/l; (5) bilirubin ≤ 50 μmol/l; (6) ast and alt \< 5 × upper limit of normal (uln) and alkaline phosphatase \< 4 × uln; (7) extended prothrombin time \< 6 seconds of uln; and (8) serum creatinine \< 1.5 × uln. exclusion criteria: 1. history of liver and adjacent tissue radiation; 2. medical history of hepatic decompensation, such as hepatic encephalopathy and esophageal or gastric variceal bleeding; 3. extrahepatic spread; 4. combination with other malignant diseases; 5. contraindications for tace; 6. pregnant and lactating women; 7. severe dysfunction of the heart, kidney, or other organs; 8. hypersensitivity to intravenous contrast agents; 9. with hiv, syphilis infection; 10. allogeneic organ transplant recipients; 11. suffering from mental and psychological diseases may affect informed consent; 12. unable to take oral medication; 13. active gastric or duodenal ulcers within 3 months before enrollment.